Ronac Mamtani, MD, MSCE
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Office: 2156627606
Fax: (215) 349-8551
Fax: (215) 349-8551
Email:
ronac.mamtani@uphs.upenn.edu
ronac.mamtani@uphs.upenn.edu
Education:
BS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Permanent linkBS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Selected Publications
Wang X, Rothen J, Huang S, Long JB, Soulos PR, Goldberg SB, Mamtani R, Presley CJ, Kunst N, Ma S, Wang SY, Gross CP, Dinan MA.: Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncol Apr 2025.Wang X, Long JB, Rothen J, Soulos PR, Robinson TJ, Presley CJ, Goldberg SB, Mamtani R, Wang SY, Kunst N, Ma S, Huang S, Gross CP, Dinan MA.: BPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era. J Natl Compr Canc Netw 23, Mar 2025.
Geynisman DM, Chepynoga K, Yates G, Tate A, Kurt M, Patel MY, Teitsson S, Mitra S, Mamtani R.: Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial. Clin Genitourin Cancer Mar 2025.
Mamtani R, Matsubara N, Pino AM, Herranz UA, Şendur MAN, Gravis G, Huillard O, Lee HJ, Gafanov R, Joly F, Bedke J, Sella A, Chang YH, Imai K, Moreno BH, Xu JZ, Alva A, Powles T.: Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial. Clin Genitourin Cancer 23: 102248, Feb 2025.
Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C.: Evolving racial/ethnic disparities in AML survival in the novel therapy era. Blood Adv 9: 533-544, Feb 2025.
Stalker M, Qu K, Cohen RB, Mamtani R, Hwang WT, Sun L.: "Off-Label" Use of Checkpoint Inhibitors in Patients With Negative or Unknown PD-L1 Status in Advanced Head and Neck Cancer. J Natl Compr Canc Netw Feb 2025.
Orcutt X, Chen K, Mamtani R, Long Q, Parikh RB.: Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations. Nat Med Jan 2025.
Fléchon A, Morales-Barrera R, Powles T, Alva A, Özgüroğlu M, Csöszi T, Loriot Y, Rodriguez-Vida A, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Gunduz S, Mamtani R, Yu EY, Montesa Pino A, Anido U, Sendur MAN, Gravis G, Révész J, Kostorov V, Huillard O, Ma J, Rajasagi M, Vajdi A, Lunceford J, Cristescu R, Imai K, Homet Moreno B, Matsubara N.: Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma. Clin Cancer Res 30: 5353-5364, Dec 2024.
Guadamuz JS, Wang X, Altomare I, Camelo Castillo W, Sarkar S, Mamtani R, Calip GS.: Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer, 2011-2023. JNCI Cancer Spectr 8(5), Sept 2024.
Barsouk A, Elghawy O, Yang A, Sussman JH, Mamtani R, Mei L: Meta-Analysis of Age, Sex, and Race Disparities in the Era of Contemporary Urothelial Carcinoma Treatment. Cancers 16(19), Sept 2024.